159 related articles for article (PubMed ID: 7540878)
61. The relationship between clinical signs and hypercoagulable state in toxemia of pregnancy.
Terao T; Maki M; Ikenoue T; Gotoh K; Murata M; Iwasaki H; Shibata J; Nakabayashi M; Muraoka M; Takeda Y
Gynecol Obstet Invest; 1991; 31(2):74-85. PubMed ID: 1828053
[TBL] [Abstract][Full Text] [Related]
62. Effect of high-dose progestogen on hemostatic properties of blood in patients with endometrial cancer.
Kaibara M; Watanabe T; Ooka F; Liang SG; Aisaka K; Okinaga S
Clin Hemorheol Microcirc; 2001; 24(2):93-9. PubMed ID: 11381184
[TBL] [Abstract][Full Text] [Related]
63. The clinical significance of TAT, PIC, TM, and t-PAIC in vascular events of BCR/ABL-negative myeloproliferative neoplasms.
Huang K; Mo Q; Liao C; Feng S; Liu G; Jiang D; Lei P
Clin Exp Med; 2024 May; 24(1):107. PubMed ID: 38776019
[TBL] [Abstract][Full Text] [Related]
64. Clinico-pharmacological studies with recombinant hirudin.
Markwardt F; Nowak G; Stürzebecher J; Vogel G
Thromb Res; 1988 Dec; 52(5):393-400. PubMed ID: 3222782
[TBL] [Abstract][Full Text] [Related]
65. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
Schiele F; Vuillemenot A; Kramarz P; Kieffer Y; Soria J; Soria C; Camez A; Mirshahi MC; Bassand JP
Thromb Haemost; 1994 May; 71(5):558-62. PubMed ID: 8091380
[TBL] [Abstract][Full Text] [Related]
66. Plasmin-alpha 2-plasmin inhibitor complex in plasma of patients with disseminated intravascular coagulation.
Takahashi H; Hanano M; Takizawa S; Tatewaki W; Shibata A
Am J Hematol; 1988 Jul; 28(3):162-6. PubMed ID: 2457307
[TBL] [Abstract][Full Text] [Related]
67. Studies on changes in parameters of the coagulation and fibrinolysis in association with extracorporeal shock wave lithotripsy.
Umekawa T; Kohri K; Yamate T; Amasaki N; Ishikawa Y; Kurita T
Urol Int; 1993; 50(3):159-63. PubMed ID: 8465483
[TBL] [Abstract][Full Text] [Related]
68. Lipid-related hemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis.
Kario K; Matsuo T
Atherosclerosis; 1993 Nov; 103(2):131-8. PubMed ID: 8292090
[TBL] [Abstract][Full Text] [Related]
69. Increased hemostatic molecular markers in patients undergoing anticoagulant therapy.
Wada H; Ikuma H; Mori Y; Shimura M; Hiyoyama K; Nakasaki T; Onoda K; Yamada N; Ohta T; Nishioka J; Sakuragawa N; Shiku H
Semin Thromb Hemost; 2000; 26(1):113-8. PubMed ID: 10805292
[TBL] [Abstract][Full Text] [Related]
70. [Clinical usefulness of the measurements of plasmin-alpha 2-plasmin inhibitor complex and plasma tissue factor activity in patients with disseminated intravascular coagulation].
Fukuda C; Iijima K; Nakamura K
Rinsho Byori; 1996 Aug; 44(8):750-6. PubMed ID: 8816061
[TBL] [Abstract][Full Text] [Related]
71. Changes in plasma levels of prothrombin fragment F 1 + 2 in cases of disseminated intravascular coagulation.
Asakura H; Shiratori Y; Jokaji H; Saito M; Uotani C; Kumabashiri I; Morishita E; Yamazaki M; Matsuda T
Acta Haematol; 1993; 89(1):22-5. PubMed ID: 8480481
[TBL] [Abstract][Full Text] [Related]
72. Comparison of the responses of global tests of coagulation with molecular markers of neutrophil, endothelial, and hemostatic system perturbation in the baboon model of E. colisepsis--toward a distinction between uncompensated overt DIC and compensated non-overt DIC.
Wada H; Yamamuro M; Inoue A; Shiku H; Sakuragawa N; Redl H; Peer G; Taylor FB
Thromb Haemost; 2001 Dec; 86(6):1489-94. PubMed ID: 11776318
[TBL] [Abstract][Full Text] [Related]
73. [Significance of factors of coagulation and fibrinolysis in progression of lung cancer].
Nagayama M; Tachibana A; Hayakawa H; Sato A
Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Feb; 31(2):180-5. PubMed ID: 8390588
[TBL] [Abstract][Full Text] [Related]
74. [Thrombin.antithrombin III complex].
Matsuo T; Kario K; Matsuo M
Rinsho Byori; 1991 Jul; 39(7):701-6. PubMed ID: 1920862
[TBL] [Abstract][Full Text] [Related]
75. [Prevention and early diagnosis of disseminated intravascular coagulation].
Matsuda T
Nihon Naika Gakkai Zasshi; 1993 Sep; 82(9):1375-82. PubMed ID: 8245630
[No Abstract] [Full Text] [Related]
76. Blood coagulation and fibrinolysis in eclamptic patients and their correlation with the clinical signs.
Halim A; Bhuiyan AB; Azim FA; Khatun S; Kanayama N; el Maradny E; Maehara K; Hiroshi K; Terao T
Gynecol Obstet Invest; 1995; 39(2):97-102. PubMed ID: 7772198
[TBL] [Abstract][Full Text] [Related]
77. Circulating hepatocyte growth factor as an independent prognostic factor of disseminated intravascular coagulation.
Chung S; Kim JE; Kim JY; Lee DS; Han KS; Kim HK
Thromb Res; 2010 Jun; 125(6):e285-93. PubMed ID: 20185166
[TBL] [Abstract][Full Text] [Related]
78. [Changes in coagulation parameters during the clinical courses of recipients of living-related partial liver transplantation].
Okumura N; Matsuzawa A; Terasawa F; Sasaki Y; Nakagoshi R; Ishikawa S; Hashikura Y; Matsunami H; Kawasaki S; Makuuchi M
Rinsho Byori; 1995 Aug; 43(8):829-35. PubMed ID: 7474443
[TBL] [Abstract][Full Text] [Related]
79. Effect of heparin, hirudin, and a synthetic thrombin inhibitor on antithrombin III in thrombin-induced disseminated intravascular coagulation in rats.
Hauptmann J; Brüggener E; Markwardt F
Haemostasis; 1987; 17(6):321-8. PubMed ID: 3428717
[TBL] [Abstract][Full Text] [Related]
80. Physical exertion induces thrombin formation and fibrin degradation in patients with peripheral atherosclerosis.
Mustonen P; Lepäntalo M; Lassila R
Arterioscler Thromb Vasc Biol; 1998 Feb; 18(2):244-9. PubMed ID: 9484989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
